At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 64 enrolled
Drug / intervention
V710 (30 µg) with MAA +1 morebiological
Likely dose
V710 (30 µg) with MAAfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With Merck Aluminum Adjuvant or Without Merck Aluminum Adjuvant in Healthy Adults 18 to 70 Years of Age
In Brief
A Phase 1 clinical trial evaluating V710 (30 µg) with MAA and V710 (30 µg) without MAA for Staphylococcal Infections. Completed, enrolled 64 participants.
Detailed Summary
The purpose of this study was to evaluate the safety, tolerability, and immunogenicity of the Merck 0657nI S. aureus vaccine (V710) either with or without Merck Aluminum Adjuvant (MAA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStaphylococcal Infections
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
Primary CompletionOct 2007
First PostedMar 2011
TodayJul 2026
First PostedMar 29, 2011
Enrollment StartSep 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.3 years ago
Interventions
V710 (30 µg) with MAAbiological
Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
V710 (30 µg) without MAAbiological
Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly